Tyra Biosciences, Inc.
TYRANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TYRA. That does not mean none is planned.
Get an email about TYRA's next catalysts
Track Tyra Biosciences (TYRA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming, 1 past
TYRA-300 Phase 2 Est. Readout (SURF301)
Estimated primary completion for TYRA-300 trial (NCT05544552) in Locally Advanced Urothelial Carcinoma. Topline data typically follows completion by weeks to months.
57% complete response rate reported in Phase 2 trial of dabogratinib; article questions whether results support advancing to Phase 3.
SourceHow TYRA's past catalysts played out
Market Overview
Stock performance and key metrics
TYRA-300
Locally Advanced Urothelial Carcinoma
Dabogratinib (TYRA-300)
Low Grade Upper Tract Urothelial Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TYRA-300 | Phase 2 | Locally Advanced Urothelial Carcinoma | - | - |
Dabogratinib (TYRA-300) | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Tyra Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Tyra Biosciences, Inc.'s (TYRA) pipeline across Phase 2. Its lead program is TYRA-300 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tyra Biosciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Tyra Biosciences, Inc. (TYRA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TYRA biotech catalysts?→
Add TYRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tyra Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.